Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients Ma, X., Lalezari, J., Tuan Nguyen, Bae, H., Schiff, E. R., Fung, S., Yuen, M., Hassanein, T., Hann, H., Elkhashab, M., Dieterich, D., Sulkowski, M., Kwo, P., Nahass, R., Agarwal, K., Ramji, A., Park, J., Ravendhran, N., Chan, S., Weilert, F., Han, S., Ayoub, W., Gane, E., Jacobson, I., Bennett, M., Huang, Q., Yan, R., Huey, V., Ruby, E., Liaw, S., Colonno, R., Lopatin, U. ELSEVIER SCIENCE BV. 2019: E130

View details for Web of Science ID 000463481700231